Schott Pharma AG KGaASHTPY -42.88%64 Return-on-Tangible-Asset is 7.76% as of Mar. 2026, which is 41% below its 10-year median of 13.12. GuruFocus rates SHTPY with a GF Score™ of 64/100 and a GF Value™ of $7.02. The stock has 2 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 80.37% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Schott Pharma AG KGaA's annualizedNet Income for the quarter that ended in Mar. 2026 was $143 Mil. Schott Pharma AG KGaA's average total tangible assets for the quarter that ended in Mar. 2026 was $1,849 Mil. Therefore, Schott Pharma AG KGaA's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 7.76%.
The historical rank and industry rank for Schott Pharma AG KGaA's Return-on-Tangible-Asset or its related term are showing as below:
SHTPY'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 9.31 Med: 13.12 Max: 15.82
Current: 9.31
During the past 6 years, Schott Pharma AG KGaA's highest Return-on-Tangible-Asset was 15.82%. The lowest was 9.31%. And the median was 13.12%.
SHTPY's Return-on-Tangible-Asset is ranked better than 80.37% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs SHTPY: 9.31
Schott Pharma AG KGaA (OTCPK:SHTPY) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Schott Pharma AG KGaA Return-on-Tangible-Asset Related Terms
Schott Pharma AG KGaA Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA Return-on-Tangible-Asset Chart
SHTPY vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 7.76% mean?
Schott Pharma AG KGaA (SHTPY) has a Return-on-Tangible-Asset of 7.76% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Schott Pharma AG KGaA and its competitors. This is 41% below median its historical median of 13.12. Over the past decade, Schott Pharma AG KGaA's Return-on-Tangible-Asset has ranged from 9.31 to 15.82. According to the industry distribution chart, Schott Pharma AG KGaA ranks #168 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 19.6%.
Is Schott Pharma AG KGaA's Return-on-Tangible-Asset too high?
Schott Pharma AG KGaA's current Return-on-Tangible-Asset of 7.76% is 41% below median its 10-year median of 13.12. Over the past 10 years, this metric has ranged from a low of 9.31 to a high of 15.82. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Schott Pharma AG KGaA's value of 7.76% is 1204.2% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #168 out of 856 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #168 out of 856 companies for Return-on-Tangible-Asset. This places Schott Pharma AG KGaA in the top 20% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.60. Schott Pharma AG KGaA's value of 7.76% is 1204.2% above this benchmark. Historically, Schott Pharma AG KGaA's own Return-on-Tangible-Asset has ranged from 9.31 to 15.82 over the past decade. While the company's 10-year median is 13.12 vs. the industry median of 0.60, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current Return-on-Tangible-Asset of 7.76% is 1204.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Return-on-Tangible-Asset is 7.76%, which is 41% below median its own 10-year median of 13.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current Return-on-Tangible-Asset of 7.76%. The stock's GF Value™ is $7.02, compared to a current price of $4.37 — trading 37.7% below its estimated fair value. The current Return-on-Tangible-Asset is 7.76%, which is 41% below median its 10-year median of 13.12 and 1204.2% above the Medical Devices & Instruments industry median of 0.60. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current Return-on-Tangible-Asset is 7.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.
Key valuation signals for SHTPY:
Return-on-Tangible-Asset: 7.76% (41% below median its 10-year median of 13.12)
GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
Industry Position: 1204.2% above the Medical Devices & Instruments median (#168 of 856)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score
Get the complete analysis for SHTPY
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
